Dellia Q2 2026 slides: record demand meets Nordic guidance cut

Dellia reported Q2 2026 revenue of NOK 167m (+5% y/y) alongside record Nordic sellout of 5.8m units (+29%), but management cut its full-year revenue outlook by nearly 20% to reflect retailer inventory overhang suppressing orders. Gross margin expanded to 41.1% (from 35.1%), yet EBIT fell 57% to NOK 9m due to NOK 7.8m in integration/consulting costs and higher investment spending. Looking ahead, Nordic outlook was reduced to ~NOK 650m (from NOK 810m) and Europe guidance was set at NOK 50–100m for FY2026, while Kirirom acquisition (expected to close Sep 2026) is positioned to improve leverage as results are expected to materialize in 2027.

Analysis

The market is likely over-penalizing a timing mismatch between sell-through and sell-in. If retailer inventory normalizes over the next 1-2 quarters, reported revenue can reaccelerate without requiring any step-up in consumer demand, which matters because the stock is already pricing a stalled growth narrative. The cleaner signal is cash conversion: improved operating cash flow and a solid balance sheet reduce dilution risk, so the real bear case is not solvency but a slower-than-expected path to operating leverage.

Competitive dynamics are more nuanced than the headline guide cut suggests. Nordic share gains imply the brand is still winning wallet share, but Sweden’s weaker performance hints that incumbents are willing to defend shelf space where the category is more mature. In Europe, the new listings are more important as a proof-of-distribution model than as immediate P&L contributors; the first 3-6 months will mostly be trade spend, field force cost, and retailer education, with real revenue inflection dependent on repeat orders into 2027.

The contrarian miss is that this may be a self-funded expansion story, not a distressed growth story. With freight and FX helping margins and external funding risk low, downside should be bounded unless sell-through decelerates or the new geographies fail to convert from trial to reorder. The key falsifier is not another soft quarter per se, but evidence that inventory digestion lasts beyond Q4 and that European listings fail to create a sustained reorder curve.

Key Decisions for Investors

• Initiate a small tactical long in DELIA only on weakness near the recent low, with a 6-12 month target tied to 2027 breakeven credibility; stop out if Q3/Q4 revenue stays constrained after retailer inventory normalization.
• Do not short DELIA here: the base case downside is limited by cash strength, while upside can accelerate sharply if European trials convert into repeat orders.
• Set a catalyst watch on TSCDY (Tesco): if the 290-store trial extends beyond the initial window or expands meaningfully before Christmas, add to DELIA longs; if Tesco does not reorder, treat the Europe thesis as delayed, not broken.
• Use the next reported quarter as the key entry point, not the current print: wait for evidence that sell-out continues to outrun sell-in before sizing above a starter position.
• Thesis falsifier: if management cannot show Nordic growth stabilization and Europe remains at the low end of guidance into Q1 2027, exit the long and treat the model as a higher-cost brand builder rather than a compounding growth asset.